Kuros Biosciences Ltd. (CH:KURN)
:KURN
Want to see CH:KURN full AI Analyst Report?
KURN Stock Chart & Stats
CHF28.16
-CHF0.35(-1.68%)
At close: 4:00 PM EST
CHF28.16
-CHF0.35(-1.68%)
Day’s Range― - ―
52-Week RangeCHF18.70 - CHF34.20
Previous CloseN/A
Volume98.33K
Average Volume (3M)128.87K
Market Cap
CHF857.60M
Enterprise ValueCHF845.88M
Total Cash (Recent Filing)CHF15.66M
Total Debt (Recent Filing)CHF3.94M
Price to Earnings (P/E)498.6
Beta1.46
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding39,411,980
10 Day Avg. Volume110,510
30 Day Avg. Volume128,868
Financial Highlights & Ratios
PEG Ratio-3.21
Price to Book (P/B)15.78
Price to Sales (P/S)8.71
P/FCF Ratio-439.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF38.00Price Target Upside34.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.35
Revenue Forecast (FY)CHF200.65M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained, multi-year top-line scaling demonstrates durable commercial traction for the MagnetOs portfolio across orthopedic and spine procedures. This revenue ramp signals expanding surgeon adoption and formulary penetration, which supports continued operating leverage and future margin expansion if the trend persists.
High Gross MarginsVery high gross margins indicate strong product-level profitability and pricing power for the synthetic bone grafts. High gross margins provide structural room to absorb commercial and R&D investment while protecting operating profits, making margin sustainability a durable advantage versus lower-margin competitors.
Conservative Balance SheetA low-leverage balance sheet gives the company financial flexibility to fund commercialization, capex, or clinical activities without heavy interest burdens. This conservatism reduces bankruptcy risk and supports multi-quarter resilience, enabling strategic optionality for partnerships or selective investments.
Bears Say
Weak Cash ConversionEarnings improvement has not yet translated into consistent cash generation; negative operating and free cash flow indicate working-capital or investment drains. If cash conversion remains weak over multiple quarters, the company may need external funding, increasing dilution or interest costs and constraining strategic actions.
Thin Profitability CushionReported profitability is now positive but slim, leaving limited buffer against reimbursement shifts, pricing pressure, or higher SG&A/R&D. Small adverse changes in procedure volumes, payer policy, or cost structure could quickly erode margins and reverse the recent profit inflection.
Near-term Funding SensitivityThe combination of negative free cash flow and recent investments raises the risk that recurring internal cash will be insufficient for growth investments. Persistent negative FCF elevates the probability of equity or debt raises, which could dilute shareholders or increase leverage, affecting long-term strategic execution.
Kuros Biosciences News
KURN FAQ
What was Kuros Biosciences Ltd.’s price range in the past 12 months?
Kuros Biosciences Ltd. lowest stock price was CHF18.70 and its highest was CHF34.20 in the past 12 months.
What is Kuros Biosciences Ltd.’s market cap?
Kuros Biosciences Ltd.’s market cap is CHF857.60M.
When is Kuros Biosciences Ltd.’s upcoming earnings report date?
Kuros Biosciences Ltd.’s upcoming earnings report date is Aug 13, 2026 which is in 81 days.
How were Kuros Biosciences Ltd.’s earnings last quarter?
Kuros Biosciences Ltd. released its earnings results on Mar 10, 2026. The company reported CHF0.093 earnings per share for the quarter, beating the consensus estimate of CHF0 by CHF0.093.
Is Kuros Biosciences Ltd. overvalued?
According to Wall Street analysts Kuros Biosciences Ltd.’s price is currently Undervalued.
Does Kuros Biosciences Ltd. pay dividends?
Kuros Biosciences Ltd. does not currently pay dividends.
What is Kuros Biosciences Ltd.’s EPS estimate?
Kuros Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kuros Biosciences Ltd. have?
Kuros Biosciences Ltd. has 39,411,980 shares outstanding.
What happened to Kuros Biosciences Ltd.’s price movement after its last earnings report?
Kuros Biosciences Ltd. reported an EPS of CHF0.093 in its last earnings report, beating expectations of CHF0. Following the earnings report the stock price went up 10.609%.
Which hedge fund is a major shareholder of Kuros Biosciences Ltd.?
Currently, no hedge funds are holding shares in CH:KURN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kuros Biosciences Ltd.
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.
KURN Company Deck
KURN Earnings Call
Q4 2026
0:00 / 0:00
KURN Stock 12 Month Forecast
Average Price Target
CHF38.00
▲(34.94% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Options Prices
Currently, No data available
---